Takeda Pharmaceutical (TAK) Liabilities from Discontinued Operations (2018 - 2026)

Takeda Pharmaceutical's Liabilities from Discontinued Operations history runs 8 years deep, the most recent figure standing at 5216017.89 for Q1 2026.

• On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 5216017.89 in Q1 2026; TTM through Mar 2026 was 5216017.89, a N/A change from a year earlier, with the FY2026 full-year figure at 5434125.06, changed N/A from the prior year.
• Liabilities from Discontinued Operations climbed to 5216017.89 in Q1 2026 per TAK's latest filing, from 5094354.11 in the prior quarter.
• Across five years, Liabilities from Discontinued Operations topped out at 9514418.08 in Q1 2024 and bottomed at 1088635.11 in Q1 2023.
• The 5-year median for Liabilities from Discontinued Operations is 5460781.27 (2022), against an average of 6134354.12.
• Biggest YoY gain for Liabilities from Discontinued Operations was 773.98% in 2024; the steepest drop was 773.98% in 2024.
• Year by year, Liabilities from Discontinued Operations stood at 8302867.7 in 2022, then sank by 86.89% to 1088635.11 in 2023, then jumped by 745.6% to 9205448.04 in 2024, then sank by 44.66% to 5094354.11 in 2025, then climbed by 2.39% to 5216017.89 in 2026.
• Per Business Quant, the three latest TAK Liabilities from Discontinued Operations figures stand at 5216017.89 (Q1 2026), 5094354.11 (Q4 2025), and 4947547.39 (Q3 2025).